Amneal Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 ($3,146 Mil) to Dec. 2025 ($3,964 Mil) and
increased
from Dec. 2025 ($3,964 Mil) to Mar. 2026 ($3,965 Mil).
Amneal Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($1,861 Mil) to Dec. 2024 ($2,454 Mil) and
increased
from Dec. 2024 ($2,454 Mil) to Dec. 2025 ($3,964 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amneal Pharmaceuticals's Enterprise Value for Today is $7,995 Mil.
Amneal Pharmaceuticals (NAS:AMRX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amneal Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (AMRX) has a Market Cap of $5,500 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #72 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 7%.
Is Amneal Pharmaceuticals' Market Cap too high?
Amneal Pharmaceuticals' current Market Cap is $5,500 Mil. The Drug Manufacturers industry median Market Cap is 205.37. Amneal Pharmaceuticals' value of $5,500 Mil is 2578.1% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #72 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Market Cap compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #72 out of 1023 companies for Market Cap. This places Amneal Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. Amneal Pharmaceuticals' value of $5,500 Mil is 2578.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current Market Cap of $5,500 Mil is 2578.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current Market Cap is $5,500 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.57, compared to a current price of $17.24 — trading 127.7% above its estimated fair value. The current Market Cap is $5,500 Mil and 2578.1% above the Drug Manufacturers industry median of 205.37. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Market Cap is $5,500 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.24 is trading 127.7% above its estimated GF Value™ of $7.57.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
Market Cap: $5,500 Mil
GF Value™: $7.57 vs. price of $17.24 (127.7% above fair value)
Industry Position: 2578.1% above the Drug Manufacturers median (#72 of 1023)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score
Get the complete analysis for AMRX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
